Drug Combination Details
| General Information of the Combination (ID: C60643) | |||||
|---|---|---|---|---|---|
| Name | Shikonin NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| BxPC-3 | CVCL_0186 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| AsPC-1 | CVCL_0152 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Tumors were established by subcutaneous injection of 5*106 BxPC-3 cells into the flanks of male nude BALB/c mice. | |||||
| Experimental
Result(s) |
Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | RALBP1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | RIPK3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | AsPC-1 | CVCL_0152 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| SW1990 | CVCL_1723 | Pancreatic adenocarcinoma | Homo sapiens | |||
| PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Capan-2 | CVCL_0026 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| In-vivo Model | PANC-1 cells suspension (5*107 cells) was injected subcutaneously into the right anterior armpit of female nude mice. | |||||
| Experimental
Result(s) |
Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1/RIP3 and synergizes the activity of gemcitabine. | |||||
